Full-year revenue fell to $3.9 million from $5.6 million year-over-year, driven by lower AgPlenus activity and a Q4 slump to $0.3 million. The company recorded a $2.2 million impairment on Casterra’s seed inventory, contributing to a net loss of $7.8 million. The company generated $5.7 million from discontinued operations compared to a $3.2 million loss last year and expects Lavie Bio and MicroBoost sale proceeds to fund operations through mid-2026. Management highlighted upcoming BMC128 licensing milestones with Lishan Pharmaceuticals and further ChemPass AI collaboration agreements as potential catalysts. Evogene expanded human health and agriculture alliances with Bayer and Corteva and launched a second collaboration with Google Cloud to deploy advanced AI agents. The firm is concentrating resources on its ChemPass generative AI engine to enhance small-molecule discovery in pharmaceuticals and crop chemicals. Evogene streamlined operations by divesting non-core activities and resizing its workforce, cutting operating expenses from $22 million in 2024 to $13.8 million in 2025. General and administrative costs fell to $4.3 million and sales and marketing expenses declined to $1.5 million.